The Journal of invasive cardiology · 2026
Clinical outcomes after transcatheter aortic valve replacement by sex and subtype of low-flow aortic stenosis.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Galvani Eileen, Akinmolayemi Oludamilola, Swaminathan Srivatsan, Mannina Carlo, Khera Sahil, Safi Lucy M, Tang Gilbert H L, Sharma Samin K, Kini Annapoorna S, Lerakis Stamatios
Аннотация
OBJECTIVES: Prior studies suggest sex differences in clinical outcomes following transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis (AS). The authors hypothesized that among patients with low-flow aortic stenosis (LFAS), outcomes differ based on sex and subtype of LFAS: classical (cLFLG), paradoxical (pLFLG), and high gradient (LFHG).
METHODS: This single-center, observational, longitudinal cohort study included adults with LFAS who underwent TAVR. Differences in clinical outcomes (all-cause mortality, heart failure hospitalization [HFH], and myocardial infarction [MI]) by subtype of LFAS within each sex were examined via Kaplan Meier curves. Log rank P-values were reported.
RESULTS: A total of 599 patients with LFAS were followed for 12 months after TAVR. Of the male patients (n = 373), 25.2% had LFHG, 32.7% cLFLG, and 42.1% pLFLG AS. Of females (n = 226), 26.1% had LFHG, 13.3% cLFLG, and 60.6% pLFLG AS. Event rates in males were 13.1% all-cause mortality, 6.2% HFH, and 0.8% MI. Event rates in females included 6.6% all-cause mortality, 8.0% HFH, and 0 MI. In males, the LFHG vs cLFLG vs pLFLG subtypes demonstrated significant differences in time to all-cause mortality (P < .001), HFH (P = .014), and MI (P = .045).
CONCLUSIONS: In this cohort, clinical outcomes in males significantly differed by subtype of LFAS, whereas these differences were not found in females.
METHODS: This single-center, observational, longitudinal cohort study included adults with LFAS who underwent TAVR. Differences in clinical outcomes (all-cause mortality, heart failure hospitalization [HFH], and myocardial infarction [MI]) by subtype of LFAS within each sex were examined via Kaplan Meier curves. Log rank P-values were reported.
RESULTS: A total of 599 patients with LFAS were followed for 12 months after TAVR. Of the male patients (n = 373), 25.2% had LFHG, 32.7% cLFLG, and 42.1% pLFLG AS. Of females (n = 226), 26.1% had LFHG, 13.3% cLFLG, and 60.6% pLFLG AS. Event rates in males were 13.1% all-cause mortality, 6.2% HFH, and 0.8% MI. Event rates in females included 6.6% all-cause mortality, 8.0% HFH, and 0 MI. In males, the LFHG vs cLFLG vs pLFLG subtypes demonstrated significant differences in time to all-cause mortality (P < .001), HFH (P = .014), and MI (P = .045).
CONCLUSIONS: In this cohort, clinical outcomes in males significantly differed by subtype of LFAS, whereas these differences were not found in females.